Current strategies of blood doping detection

The Effects of Exercise Training on Plasma Volume Variations: A Systematic Review

The aim of this systematic review was to summarize the evidence on the acute and long-term effects of exercise training on PV, in both trained and untrained individuals and to examine associations between changes in %PVV and change in physical/physiological performance. Despite the status of participants and the exercise duration or intensity, all the acute studies reported a significant decrease of PV (effect size: 0.85<d<3.45, very large), and ranged between 7 and 19.9%. In untrained individuals, most of studies reported a significant increase of PV in response to different kind of training including endurance training and high intensity interval training (effect size: 0.19<d<3.52, small to very large), and ranged from 6.6 to 16%. However, in trained individuals the results are equivocal. We showed that acute exercise appears to induce a significant decrease of PV in both healthy untrained and trained individuals in response to several exercise modalities. Moreover, there is evidence that long-term exercise training induced a significant increase of PV in healthy untrained individuals. However, it seems that there is no consensus concerning the effect of long-term exercise training on PV in trained individuals.

DropWise: current role and future perspectives of dried blood spots (DBS), blood microsampling, and their analysis in sports drug testing

For decades, blood testing has been an integral part of routine doping controls. The breadth of information contained in blood samples has become considerably more accessible for anti-doping purposes over the last 10 years through technological advancements regarding analytical instrumentation as well as enhanced sample collection systems. Particularly, microsampling of whole blood and serum, for instance as dried blood spots (DBS), has opened new avenues in sports drug testing and substantially increased the availability and cost-effectiveness of doping control specimens. Thus, microvolume blood specimens possess the potential to improve monitoring of blood hormone and drug levels, support evaluation of circulating drug concentrations in competition, and enhance the stability of labile markers and target analytes in blood passport analyses as well as peptide hormone and steroid ester detection. Further, the availability of the fraction of lysed erythrocytes for anti-doping purposes warrants additional investigation, considering the sequestering capability of red blood cells (RBCs) for certain substances, as a complementary approach in support of the clean sport.

Establishment of a post-race biomarkers database and application of pathway analysis to identify potential biomarkers in post-race equine plasma

In the context of doping control, conventional direct chemical testing detects only a limited scope of target substances in equine biological samples. To expand the ability to detect doping agents and their detection windows, metabolomics has recently become a common approach for monitoring alteration of biomarkers caused by doping agents in relevant metabolic pathways. In horse racing, remarkable changes in metabolic profiles between the rest state and racing are likely to affect the identification of doping biomarkers. Previously, we reported a limited number of significantly upregulated metabolites after racing, based on a non-targeted metabolomics approach using out-of-competition and post-race equine plasma samples. In this study, we performed a more thorough analysis of the data set, using pathway analysis to establish a post-race biomarkers database (PBD) that includes upregulated and downregulated metabolites, their fold changes, and relevant pathways, with the main objective of improving our understanding of changes in physiological status related to horse racing. Statistical analysis of the PBD revealed that two peak combinations of pentadecanoyl carnitine/galactosylglycerol (P/G) and heptadecanoyl carnitine/galactosylglycerol (H/G) could be used as potential biomarkers for the discrimination of the rest and post-race groups. To demonstrate the applicability of the PBD, we validated the post-race biomarkers P/G and H/G (highly involved in lipid metabolism) by a single-blind test. This strategy, which combines establishment of a biomarker database with pathway analysis, represents a powerful tool for discovering potential doping biomarkers in the future.

Monitoring of RBC rheology after cryopreservation to detect autologous blood doping in vivo? A pilot study

BACKGROUND: Autologous blood doping (ABD) is applied to improve performance capacity. ABD includes blood donation, red blood cell (RBC) storage at –80°C and re-infusion prior to or during competition. ABD is not directly detectable with current detection techniques. OBJECTIVE: Since cryopreservation is known to affect RBC physiology in vitro, the aim of the study was to examine whether these alterations are detectable in vivo. METHODS: Blood from six healthy male donors was transferred into conventional blood bags, cryopreserved, stored for 18 weeks at –80°C and re-infused with a RBC volume corresponding to ∼4% of total blood volume into respective donor. RBC physiology parameters were measured before blood donation/re-infusion, and 0/1/2/6/24/48/72 h and 1 w post re-infusion. RESULTS: RBC parameters and age markers were unaffected during intervention. RBC deformability increased from pre-blood-sampling to pre-re-infusion while deformability and viscosity values remained unaltered post re-infusion. RBC nitric oxide associated analytes, metabolic parameters and electrolyte concentrations remained unaffected. CONCLUSIONS: The data of this pilot study indicate that the increase in RBC deformability might be related to neoformation of RBC after blood donation. The lack of changes in tested parameters might be related to the low re-infused RBC volume which might explain differences to in vitro results.

Erythropoietin as a performance-enhancing drug: Its mechanistic basis, detection, and potential adverse effects

Erythropoietin (EPO) is the main hormone regulating red blood cell (RBC) production. The large-scale production of a recombinant human erythropoietin (rHuEPO) by biotechnological methods has made possible its widespread therapeutic use as well as its misuse in sports. Since the marketing of the first epoetin in 1989, the development has progressed to the third-generation analogs. However, the production of rHuEPO is costly, and the frequent administration of an injectable formula is not optimal for compliance of therapeutic patients. Hence, pharmaceutical industries are currently developing alternative approaches to stimulate erythropoiesis, which might offer new candidates for doping purposes. The hypoxia inducible factors (HIF) pathway is of particular interest. The introduction of new erythropoiesis-stimulating agents (ESAs) for clinical use requires subsequent development of anti-doping methods for detecting the abuse of these substances. The detection of ESAs is based on two different approaches, namely, the direct detection of exogenous substances and the indirect detection, for which the effects of the substances on specific biomarkers are monitored. Omics technologies, such as ironomics or transcriptomics, are useful for the development of new promising biomarkers for the detection of ESAs. Finally, the illicit use of ESAs associates with multiple health risks that can be irreversible, and an essential facet of anti-doping work is to educate athletes of these risks. The aim of this review is to provide an overview of the evolution of ESAs, the research and implementation of the available detection methods, and the side effects associated with the misuse of ESAs.

Analytical progresses of the World Anti-Doping Agency Olympic laboratories: a 2016 update from London to Rio

The 2016 Olympic and Paralympic Games, the biggest event in human sports, was held in Rio de Janeiro with more than 10,500 athletes from 206 countries over the world competing for the highest of sports honors, an Olympic medal. With the hope that the Olympic ideal accompanies all aspects of the XXXI Olympiad, WADA accredited antidoping laboratories use the spearhead of analytical technology as a powerful tool in the fight against doping. This review summarizes the main analytical developments applied in antidoping testing methodology combined with the main amendments on the WADA regulations regarding analytical testing starting from the 2012 London Olympics until the 2016 Olympic Games in Rio de Janeiro.

Effect of 3-week high-intensity interval training on VO2max, total haemoglobin mass, plasma and blood volume in well-trained athletes

PURPOSE

This study examined the haematological adaptations to high-intensity interval training (HIT), i.e. total haemoglobin mass (tHb-mass), blood volume (BV), and plasma volume (PV), and its effects on VO2max in well-trained athletes.

METHODS

Twenty-seven male and eight female well-trained (VO2max 63.7 ± 7.7 ml/min/kg) athletes were randomly assigned to the HIT (HITG, N = 19) or the control group (CG, N = 16). Over a 3-week period, the HITG performed 11 HIT sessions, consisting of four 4-min interval bouts at an exercise intensity of 90-95 % of the individual maximal heart rate (HRmax), separated by 4-min active recovery periods. Before and 5 ± 2 days after the intervention, tHb-mass, BV and PV were determined by the CO-rebreathing method. VO2max was assessed in a laboratory treadmill test.

RESULTS

tHb-mass (from 753 ± 124 to 760 ± 121 g), BV (from 5.6 ± 0.8 to 5.6 ± 0.9 l) and PV (from 3.2 ± 0.5 to 3.2 ± 0.5 l) remained unchanged after HIT and did not show an interaction (group × time). Within the HITG, VO2max improved from baseline by +3.5 % (p = 0.011), but remained unchanged in the CG. No interaction (group × time) was seen for VO2max. The HITG showed a significant reduction in HRmax compared to the baseline measurement (-2.3 %, p ≤ 0.001), but HRmax remained unchanged in the CG. There was a significant interaction (group × time) for HRmax (p = 0.006). Also, oxygen pulse significantly increased only in HITG from 22.9 ± 4.4 to 23.9 ± 4.2 ml/beat, with no interaction (p = 0.150).

CONCLUSIONS

Eleven HIT sessions added to usual training did neither improve VO2max nor haematological parameters compared to the CG.

Set-up of a multivariate approach based on serum biomarkers as an alternative strategy for the screening evaluation of the potential abuse of growth promoters in veal calves

A chemometric class modelling strategy (unequal dispersed classes - UNEQ) was applied for the first time as a possible screening method to monitor the abuse of growth promoters in veal calves. Five serum biomarkers, known to reflect the exposure to classes of compounds illegally used as growth promoters, were determined from 50 untreated animals in order to design a model of controls, representing veal calves reared under good, safe and highly standardised breeding conditions. The class modelling was applied to 421 commercially bred veal calves to separate them into 'compliant' and 'non-compliant' with respect to the modelled controls. Part of the non-compliant animals underwent further histological and chemical examinations to confirm the presence of either alterations in target tissues or traces of illegal substances commonly administered for growth-promoting purposes. Overall, the congruence between the histological or chemical methods and the UNEQ non-compliant outcomes was approximately 58%, likely underestimated due to the blindness nature of this examination. Further research is needed to confirm the validity of the UNEQ model in terms of sensitivity in recognising untreated animals as compliant to the controls, and specificity in revealing deviations from ideal breeding conditions, for example due to the abuse of growth promoters.